ARINGAGE Trademark

Trademark Overview


On Monday, April 30, 2018, a trademark application was filed for ARINGAGE with the United States Patent and Trademark Office. The USPTO has given the ARINGAGE trademark a serial number of 87900878. The federal status of this trademark filing is REGISTERED as of Tuesday, January 28, 2020. This trademark is owned by CMG Pharmaceutical Co.,Ltd.. The ARINGAGE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary preparations for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; sanitary preparations for medical purposes; biotechnological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; biological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders...
aringage

General Information


Serial Number87900878
Word MarkARINGAGE
Filing DateMonday, April 30, 2018
Status700 - REGISTERED
Status DateTuesday, January 28, 2020
Registration Number5970134
Registration DateTuesday, January 28, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 12, 2019

Trademark Statements


Goods and ServicesPharmaceutical and veterinary preparations for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; sanitary preparations for medical purposes; biotechnological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; biological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; drugs for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; pharmaceuticals for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; multivitamins preparations; pharmaceutical preparations for diagnosis for medical orveterinary purposes; nutraceutical preparations for therapeutic or medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; preparations of microorganisms for medical and veterinary use for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; antibiotics

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 9, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCMG Pharmaceutical Co.,Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressGangnam-gu, Seoul
KR

Party NameCMG Pharmaceutical Co.,Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGangnam-gu, Seoul
KR

Party NameCMG Pharmaceutical Co.,Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGangnam-gu, Seoul
KR

Trademark Events


Event DateEvent Description
Thursday, May 3, 2018NEW APPLICATION ENTERED
Wednesday, May 9, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 21, 2018ASSIGNED TO EXAMINER
Tuesday, August 21, 2018NON-FINAL ACTION WRITTEN
Tuesday, August 21, 2018NON-FINAL ACTION E-MAILED
Tuesday, August 21, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 7, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 13, 2019ASSIGNED TO LIE
Monday, February 25, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 25, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 6, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 8, 2019ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Tuesday, March 12, 2019ELECTRONIC RECORD REVIEW COMPLETE
Tuesday, March 26, 2019WITHDRAWN FROM PUB - OG REVIEW QUERY
Monday, July 1, 2019PREVIOUS ALLOWANCE COUNT WITHDRAWN
Thursday, July 11, 2019PRIORITY ACTION WRITTEN
Thursday, July 11, 2019PRIORITY ACTION E-MAILED
Thursday, July 11, 2019NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, September 25, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 25, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 26, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, October 5, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 12, 2019PUBLISHED FOR OPPOSITION
Tuesday, January 28, 2020REGISTERED-PRINCIPAL REGISTER
Thursday, November 14, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, November 14, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, November 14, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, November 14, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, January 28, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, November 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED